Pfizer Metsera acquisition: Pfizer wins $10 billion deal ending bidding war

Pfizer Metsera acquisition concluded as Pfizer Inc. agreed to buy Metsera Inc., a clinical-stage obesity drug developer, for up to $10 billion, ending a fierce bidding war with Danish rival Novo Nordisk. Pfizer’s final bid values Metsera at $86.25 per share, which includes $65.60 in cash per share plus contingent milestone payments totaling up to $20.65 per share. This offer surpassed Novo Nordisk’s last bid, and Metsera’s board unanimously recommended shareholders approve Pfizer’s proposal.​ Bidding war reaches peak and legal battles The competitive bidding began with Pfizer’s initial $4.9 billion offer made in September, followed by a series of unsolicited bids